SCHEMBL3598407

SCHEMBL3598407

CN(C)c1ccc(CCN2CCC(N(C)C(=O)O)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 14/20 0.53
OPRD1 P41143 7/20 0.53
OPRK1 P41145 7/20 0.53
ADRA1A P35348 3/20 0.53
ADRA1B P35368 3/20 0.53
SLC22A1 O15245 1/20 0.53
NR1I2 O75469 1/20 0.53
ABCB1 P08183 1/20 0.53
CHRM1 P11229 1/20 0.53
DRD2 P14416 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
CHRM3 P20309 1/20 0.53
MAOA P21397 1/20 0.53
DRD4 P21917 1/20 0.53
MAOB P27338 1/20 0.53
HRH1 P35367 1/20 0.53
DRD3 P35462 1/20 0.53
CHRNA4 P43681 1/20 0.53
SLC6A3 Q01959 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594347 0.83 OPRM1 (0.58) OPRM1OPRD1OPRK1ADRA1AADRA1B
SCHEMBL3938953 0.80 CCR4 (0.58) OPRM1OPRD1OPRK1ADRA1AADRA1B
SCHEMBL23105175 0.79 HRH3 (0.71) SIGMAR1
SCHEMBL3598405 0.79 L3MBTL1 (0.50) OPRM1OPRD1OPRK1ADRA1AADRA1B
SCHEMBL19658596 0.78 OPRM1 (0.66) OPRM1OPRD1OPRK1ADRA1AADRA1B
SCHEMBL3594122 0.78 CCR5 (0.61) OPRM1OPRD1OPRK1ADRA1AADRA1B
SCHEMBL3604727 0.78 C5AR1 (0.60) OPRM1DRD2SIGMAR1
SCHEMBL19658483 0.76 CCR5 (0.55) OPRM1OPRD1OPRK1ADRA1AADRA1B
SCHEMBL13478892 0.76 OPRM1 (0.64) OPRM1OPRD1OPRK1ADRA1AADRA1B
SCHEMBL27654942 0.76 SIGMAR1 (0.52) OPRM1DRD4KCNH2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 OPRM1 782/4885OPRD1 663/4885OPRK1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.